{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:16:43Z","timestamp":1792250203417,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejps.2026.107443","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:26:37Z","timestamp":1768350397000},"page":"107443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety, pharmacokinetics, and pharmacodynamics of GS1-144, a neurokinin-3 receptor antagonist: A randomized phase 1 single and multiple ascending dose and food effect study"],"prefix":"10.1016","volume":"220","author":[{"given":"Xiaojie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2026.107443_bib0031","doi-asserted-by":"crossref","first-page":"e4857","DOI":"10.1210\/clinem\/dgaa657","article-title":"Pharmacodynamic activity of the novel neurokinin-3 receptor antagonist SJX-653 in healthy men","volume":"105","author":"Anderson","year":"2020","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ogc.2018.07.005","article-title":"Vasomotor symptoms across the menopause transition: differences among women","volume":"45","author":"Avis","year":"2018","journal-title":"Obs. Gynecol Clin. North Am"},{"key":"10.1016\/j.ejps.2026.107443_bib0013","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3332\/ecancer.2019.909","article-title":"Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update","volume":"13","author":"Biglia","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ejps.2026.107443_bib0035","unstructured":"Center for Drug Evaluation and Research (CDER), 2022. Application number: 216578Orig1s000. Clinical Pharmacology Review(s). NDA# NDA216578. Accessed June 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216578Orig1s000ClinPharmR.pdf."},{"issue":"3","key":"10.1016\/j.ejps.2026.107443_bib0012","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2053369116632439","article-title":"Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries","volume":"22","author":"Constantine","year":"2016","journal-title":"Post. Reprod. Health"},{"issue":"2","key":"10.1016\/j.ejps.2026.107443_bib0004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jc.2014-3062","article-title":"Associations of menopausal vasomotor symptoms with fracture incidence","volume":"100","author":"Crandall","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ejps.2026.107443_bib0014","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/GME.0000000000002095","article-title":"Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of real-world evidence from US electronic health records","volume":"30","author":"DePree","year":"2023","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.ejps.2026.107443_bib0034","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.ejps.2026.107443_bib0020","unstructured":"European Medicines Agency (EMA), 2025. Vezoa (fezolinetant) summary of product characteristics. Accessed November, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veoza-epar-product-information_en.pdf."},{"issue":"9","key":"10.1016\/j.ejps.2026.107443_bib0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/GME.0000000000000196","article-title":"Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort","volume":"21","author":"Freeman","year":"2014","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ejps.2026.107443_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/gme.0b013e318185e25b","article-title":"Vasomotor symptoms are associated with a lower bone mineral density","volume":"16","author":"Gast","year":"2009","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.ejps.2026.107443_bib0001","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women\u2019s health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am. J. Public Health"},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3949\/ccjm.91a.23067","article-title":"Nonhormone therapies for vasomotor symptom management","volume":"91","author":"Iyer","year":"2024","journal-title":"Cleve Clin. J. Med"},{"issue":"12","key":"10.1016\/j.ejps.2026.107443_bib0010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1089\/jwh.2015.5670","article-title":"Hot flash frequency and blood pressure: data from the study of women\u2019s health across the nation","volume":"25","author":"Jackson","year":"2016","journal-title":"J Womens. Health (Larchmt)"},{"issue":"8","key":"10.1016\/j.ejps.2026.107443_bib0022","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"11","key":"10.1016\/j.ejps.2026.107443_bib0037","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","article-title":"Estrogen and the skeleton","volume":"23","author":"Khosla","year":"2012","journal-title":"Trend. Endocrinol. Metab"},{"issue":"10382","key":"10.1016\/j.ejps.2026.107443_bib0021","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejps.2026.107443_bib0016","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1007\/s12325-021-01900-w","article-title":"Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review","volume":"38","author":"Menown","year":"2021","journal-title":"Adv. Ther"},{"issue":"9","key":"10.1016\/j.ejps.2026.107443_bib0017","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1210\/en.2018-00389","article-title":"KNDy cells revisited","volume":"159","author":"Moore","year":"2018","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.ejps.2026.107443_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/GME.0000000000001793","article-title":"Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden","volume":"28","author":"Nappi","year":"2021","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0023","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obs. Gynecol"},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0038","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1210\/jc.2003-031539","article-title":"The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center","volume":"89","author":"Need","year":"2004","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"11","key":"10.1016\/j.ejps.2026.107443_bib0027","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial","volume":"185","author":"Panay","year":"2025","journal-title":"JAMA Intern Med."},{"issue":"16","key":"10.1016\/j.ejps.2026.107443_bib0026","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"issue":"10081","key":"10.1016\/j.ejps.2026.107443_bib0032","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(17)30823-1","article-title":"Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"389","author":"Prague","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejps.2026.107443_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","article-title":"Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes","volume":"34","author":"Rance","year":"2013","journal-title":"Front Neuroendocr."},{"issue":"1","key":"10.1016\/j.ejps.2026.107443_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13543784.2024.2305122","article-title":"Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms","volume":"33","author":"Sassarini","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2026.107443_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079525","article-title":"Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial","volume":"387","author":"Schaudig","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejps.2026.107443_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2024.108159","article-title":"Effect of fezolinetant on patient-reported quality-of-life outcomes: data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy","volume":"193","author":"Shapiro","year":"2025","journal-title":"Maturitas"},{"key":"10.1016\/j.ejps.2026.107443_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coph.2015.03.005","article-title":"Parathyroid hormone: anabolic and catabolic actions on the skeleton","volume":"22","author":"Silva","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107443_bib0029","article-title":"Sex differences in drug disposition","volume":"2011","author":"Soldin","year":"2011","journal-title":"J. Biomed. Biotechnol"},{"issue":"1","key":"10.1016\/j.ejps.2026.107443_bib0033","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-49-1-152","article-title":"LH, FSH and skin temperaure during the menopausal hot flash","volume":"49","author":"Tataryn","year":"1979","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"7","key":"10.1016\/j.ejps.2026.107443_bib0011","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"issue":"10","key":"10.1016\/j.ejps.2026.107443_bib0008","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1210\/jc.2012-1410","article-title":"Vasomotor symptoms and insulin resistance in the study of women's health across the nation","volume":"97","author":"Thurston","year":"2012","journal-title":"J. Clin. Endocrinol. Metab"},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0009","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/AOG.0b013e31824a09ec","article-title":"Vasomotor symptoms and lipid profiles in women transitioning through menopause","volume":"119","author":"Thurston","year":"2012","journal-title":"Obs. Gynecol."},{"key":"10.1016\/j.ejps.2026.107443_bib0019","unstructured":"U.S. Food and Drug Administration (FDA), 2024a. VEOZAH\u00ae (fezolinetant) U.S. Prescribing information. Accessed November, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216578s004lbl.pdf."},{"key":"10.1016\/j.ejps.2026.107443_bib0039","unstructured":"U.S. Food and Drug Administration (FDA), 2024b. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Accessed November 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due."},{"key":"10.1016\/j.ejps.2026.107443_bib0028","unstructured":"U.S. Food and Drug Administration (FDA), 2025. LYNKUET\u00ae (elinzanetant) U.S. Prescribing information. Accessed November, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219469s000lbl.pdf."},{"issue":"4","key":"10.1016\/j.ejps.2026.107443_bib0002","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.maturitas.2007.09.006","article-title":"Healthcare seeking and treatment for menopausal symptoms in the United States","volume":"58","author":"Williams","year":"2007","journal-title":"Maturitas"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:50:50Z","timestamp":1776185450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S0928098726000175"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107443","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and pharmacodynamics of GS1-144, a neurokinin-3 receptor antagonist: A randomized phase 1 single and multiple ascending dose and food effect study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107443"}}